Exhibition Time:October 8th to 11th, 2024.

Booth No.: 3D95

Guangzhou Tosun Pharmaceutical Ltd proudly participated in the CPHI Milan, attracted significant attention, and we were thrilled to connect with numerous existing and potential clients. The event proved to be an excellent platform for fostering partnerships and showcasing our extensive expertise in the pharmaceutical industry.

With over 20 years of experience, Guangzhou Tosun Pharmaceutical Ltd specializes in APIs, excipients, impurities, reference listed drugs, and intermediates. We are recognized as one of the most professional pharmaceutical suppliers in China, committed to delivering high-quality products and services to our global partners.

Export from China

1.Active Pharmaceutical Ingredient(APIs)

2.Comparator Drug(RLDs)

3.Finished Dosage Formulation(FDF)

4.Reference Standard(Impurity)

Distribution of API & FDF

1.Ready stock APIs in USP, BP, EP with DMF, Tech Pack, GMP, Written Confirmation, and all lab reports

2.We are looking for your local distributor to register and sales our FDF & API.

R&D

Synthesis of Chemical Reference Standards

Structural Elucidation of Unknown Impurity

Isolation and Purification of Active Compounds

Generic Drug Development

APls & FDF Regulatory in China

1.License In

2.Market lnvestigation

3.Medical English & Chinese Translation

Latest Developments in Active Pharmaceutical Ingredients (APIs):

Tosylate Donanemab

Hydrochloride Duloxetine

Mesylate Brexpiprazole

SGLT2 Inhibitor

Tosylate Nademedine

Malate Samidorphan

These compounds have recently been developed in our research laboratory, and we have samples available for interested parties.

Additionally, we take pride in our dedicated impurity laboratory, supported by our proprietary impurity brand, TOREF. We offer customized impurities and intermediates to meet the specific needs of our clients.

We invite anyone interested in our products or services to reach out to us for further information. Thank you to everyone who visited our booth at CPHI Milan-We look forward to future collaborations!